NASH Renaissance 2023

Pemvidutide—Potent GLP-1/Glucagon Dual Receptor Agonist for the Treatment of NASH and Obesity

Evercore ISI Research Event 30 March 2023

Saltimmune | NASDAQ: ALT

Forward-looking statements

Safe-Harbor Statement


This presentation has been prepared by Altimmune, Inc. ("we," "us," "our," "Altimmune" or the "Company") and includes certain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including statements relating to future financial or business performance, conditions, plans, prospects, trends, or strategies and other financial and business matters, including without limitation, the timing of key milestones for our clinical assets, the timing of the Phase 2b NASH clinical trial of pemvidutide, the performance of our drug candidates in ongoing and future clinical trials and the prospects for regulatory approval, commercializing or selling any product or drug candidates. In addition, when or if used in this press release, the words "may," "could," "should," "anticipate," "believe," "estimate," "expect," "intend," "plan," "predict" and similar expressions and their variants, as they relate to the Company may identify forward-looking statements. The Company cautions that these forward-looking statements are subject to numerous assumptions, risks, and uncertainties, which change over time. Important factors that may cause actual results to differ materially from the results discussed in the forward looking statements or historical experience include risks and uncertainties, including risks such as delays in regulatory review, manufacturing and supply chain interruptions, access to clinical sites, enrollment, adverse effects on healthcare systems and disruption of the global economy; the impact subject baseline characteristics, including body weight, on the success of future trials; the reliability of the results of studies relating to human safety and possible adverse effects resulting from the administration of the Company's product candidates; the Company's ability to manufacture clinical trial materials on the timelines anticipated; and the success of future product advancements, including the success of future clinical trials. Further information on the factors and risks that could affect the Company's business, financial conditions and results of operations are contained in the Company's filings with the U.S. Securities and Exchange Commission, including under the heading "Risk Factors" in the Company's latest annual report on Form 10-K and our other filings with the SEC, which are available at www.sec.gov.





PEMVIDUTIDE PHASE 1b NAFLD TRIAL WITH 12-WEEK EXTENSION

- 12-week, randomized, placebo-controlled study of 94 subjects with obesity or overweight and non-alcoholic fatty liver disease (NAFLD)
- 64 completers participated in a 12-week extension trial to receive a total of 24 weeks of treatment
- No caloric restriction or lifestyle intervention



Key Eligibility Criteria	 MRI-PDFF ≥ 10%
	 FibroScan® LSM < 10kPa
	 Non-diabetes or non-insulin dependent diabetes with HbA1c< 9.5%
	 Serum ALT ≤ 75 IU/L

		Treatment					
Baseline Characteristi	seline Characteristics		1.2 mg (n=16)	1.8 mg (n=15)	2.4 mg (n=14)		
Age, yearsmean (SD)Genderfemale, n (%)		49.0 (15)	48.6 (11)	49.9 (10)	48.4 (8)		
		11 (57.9%)	7 (43.8%)	8 (53.3%)	8 (57.1%)		
Ethnicity	Hispanic, n (%)	11 (57.9%)	15 (93.8%)	12 (80.0%)	9 (64.3%)		
BMI , kg/m²	mean (SD)	37.1 (4.9)	36.7 (6.1)	36.0 (3.8)	37.0 (5.3)		
Body weight, kg	mean (SD)	104.4 (21.2)	101.4 (16.3)	100.9 (13.2)	107.4 (17.2)		
Diabetes status	T2D, n (%)	5 (26.3%)	3 (18.8%)	6 (40.0%)	3 (21.4%)		
Liver fat content, %	mean (SD)	24.0 (9.6)	20.1 (7.7)	23.9 (7.4)	20.5 (6.5)		
Serum ALT, IU/L mean (SD)		41.0 (21.3)	32.4 (14.2)	35.3 (13.0)	39.6 (26.6)		

⊗altimmune


ROBUST REDUCTIONS IN LIVER FAT CONTENT (LFC) AT WEEK 24

SIGNIFICANT EFFECTS OBSERVED AS EARLY AS WEEK 6

Relative Reduction at Week 24

90-*** *** 75.2% 76.4% 80 Mean Relative Reduction in Liver Fat (% Change) *** 56.3% 50**-**14.0% 1.2 mg 2.4 mg 1.8 mg placebo pemvidutide

*** p < 0.001 vs. placebo (ANCOVA¹)



* p < 0.05, ** p < 0.005, *** p < 0.001, **** p < 0.0001 vs. placebo (CMH³)

pemvidutide

pemvidutide

pemvidutide

Responder Analyses at Week 24

Placebo

1.2 mg pemvidutide

1.8 mg pemvidutide


2.4 mg pemvidutide

🕅 altimmune

6

SIGNIFICANT cT1 RESPONSE RATES AND ALT REDUCTION AT WEEK 24

INDEPENDENT INDICATORS OF REDUCED LIVER INFLAMMATION




cT1 Responder Rates¹

* p < 0.05, ** p < 0.005 vs. placebo (Fisher's Exact Test)

80ms reduction in cT1 has been associated with a 2-point reduction of NASH Activity Score (NAS)²

ALT Reduction



altimmune

¹80ms reduction from baseline; ²Dennis A, Front Endocrinol 2021; ³mixed model for repeated measures

FIBROSIS IMPROVEMENT DRIVEN BY DEGREE OF LFC REDUCTION

EFFECTS ARE INDEPENDENT OF MECHANISM

Agents with Direct Effects on Liver - Fibrosis Improvement Achieved

Compound	Dose	Mechanism	Duration of Treatment	LFC Reduction	Fibrosis Improvement		
					Treatment	Placebo	Δ
Resmetirom	100 mg QD	THR-β	52 weeks	48%	26%*	14%	12%
Pegozafermin	44 mg Q2W	FGF21	24 weeks	54%	27%*	7%	20%
Efruxifermin	50 mg QW	FGF21	24 weeks	64%	41%*	20%	21%
Pemvidutide	1.8 mg QW	GLP-1/GCG	24 weeks	75%	TBD	TBD	TBD

Agents with Indirect Effects on Liver - Fibrosis Improvement Not Achieved

	Compound	und Dose	Mechanism	Duration of Treatment	LFC Reduction	Fibrosis Improvement		
	Compound					Treatment	Placebo	Δ
1	Semaglutide	0.4 mg QD	GLP-1	72 weeks	35% ¹	43%	33%	10%


🛞 altimmune


Data derived from different clinical trials with differences in trial design, patient populations and timepoints. Direct trial comparisons cannot be made.

PEMVIDUTIDE DEMONSTRATED POTENT ANTI-FIBROTIC EFFECTS AND SUPPRESSION OF PROFIBROTIC GENES IN PRECLINICAL STUDIES

Gubra Mouse NASH Model

Col1A1






Changes accompanied by suppression of stellate cell pathways and profibrotic genes

- A-SMA (ACTA2)
- Platelet-derived growth factor subunit B (PDGFB)
- Transforming growth factor-beta (TGF- β)

<u>altimmune</u>

SIGNIFICANT REDUCTIONS IN BODY WEIGHT AT WEEK 24

POTENT EFFECTS IN BOTH NAFLD AND OBESITY POPULATIONS



🛞 altimmune

¹ all subjects (diabetes and non-diabetes); ** p < 0.005. *** p < 0.001 vs. placebo (MMRM)

GLUCOSE HOMEOSTASIS MAINTAINED THROUGH WEEK 24


		Treatment					
Characteristic	Placebo	1.2 mg	1.8 mg	2.4 mg			
NON-DIABETES	· · · · · ·	N=14	N=13	N=9	N=11		
Fasting glucose							
Baseline, mg/dL	mean (SD)	96.2 (12.4)	99.4 (11.9)	96.0 (12.4)	99.3 (13.6)		
Week 24, mg/dL	mean (SD)	93.3 (12.1)	99.1 (13.1)	96.9 (12.5)	98.4 (24.5)		
HbA1c							
Baseline, %	mean (SD)	5.8 (0.2)	5.7 (0.3)	5.7 (0.2)	5.5 (0.4)		
Week 24, %	mean (SD)	5.7 (0.3)	5.8 (0.3)	5.8 (0.3)	5.6 (0.3)		
DIABETES		N=5	N=3	N=6	N=3		
Fasting glucose							
Baseline, mg/dL	mean (SD)	111.5 (19.2)	132.1 (28.2)	120.2 (37.1)	147.4 (40.4)		
Week 24, mg/dL	mean (SD)	109.4 (14.8)	123.4 (50.8)	109.0 (13.1)	75.5 (29.0)		
HbA1c							
Baseline, %	mean (SD)	6.1 (0.6)	7.8 (1.4)	6.4 (0.5)	6.8 (1.3)		
Week 24, %	mean (SD)	6.4 (1.1)	7.4 (2.3)	6.4 (0.3)	6.3 (1.3)		

🛞 altimmune

Baseline refers to Week 0 of the Phase 1b NAFLD trial

PEMVIDUTIDE—SUMMARY AND CONCLUSIONS

- Robust liver fat reduction accompanied by significant weight loss
- Potent anti-inflammatory effects (cT1 responses and ALT reductions)
- Potent anti-fibrotic effects with suppression of profibrotic genes in preclinical studies
- Initiation of Phase 2b biopsy-driven NASH trial expected mid-year 2023



NASH Renaissance 2023

Pemvidutide—Potent GLP-1/Glucagon Dual Receptor Agonist for the Treatment of NASH and Obesity

Evercore ISI Research Event 30 March 2023

Saltimmune | NASDAQ: ALT